Monitoring rhGH Safety: rhGH Registries, SAGhE and Future Needs

Bradley S Miller, Ron G. Rosenfeld

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


The safety of growth hormone (GH) therapy in children has been studied extensively. The identification of Creutzfeldt-Jacob disease in individuals who received pituitary-derived GH led to heightened surveillance for safety issues related to recombinant human GH (rhGH). An excellent safety profile of rhGH has been demonstrated in large Phase IV registries comprising > 600,000 patient-years of rhGH exposure and long-term safety cohorts of adults treated with GH as children. Increased mortality risk has been reported but eliminated when corrected for small size at birth. Increased risk of mortality from cerebrovascular disease has been reported but interpretation of these events remains difficult due to the lack of appropriate control groups and a lack of replication of these findings in other studies. The advent of new long-acting growth hormone (LAGH) products provides an opportunity for the development of cohorts of individuals receiving LAGH replacement therapy for continued long-term safety studies.

Original languageEnglish (US)
Pages (from-to)150-161
Number of pages12
JournalPediatric endocrinology reviews : PER
StatePublished - Sep 1 2018


  • Growth
  • Growth hormone
  • Safety
  • Short stature
  • Treatment

PubMed: MeSH publication types

  • Journal Article


Dive into the research topics of 'Monitoring rhGH Safety: rhGH Registries, SAGhE and Future Needs'. Together they form a unique fingerprint.

Cite this